NICE commissioning targets unveiled

NewsGuard 100/100 Score

By Caroline Price

NICE has released the full menu of Commissioning Outcomes Framework (COF) indicators that it is proposing CCG performance should be judged on from 2013.

Tied to the controversial 'Quality Premium' that individual GP practices can be awarded, the indicators cover eight key domains, and include prevention of premature deaths from cancer, mental illness and cardiovascular and respiratory diseases.

Other key indicators include emergency admissions for acute conditions not usually requiring hospital admission, as well as various patient reported outcomes for elective procedures and experience of GP out-of-hours services.

The NICE website states that "where possible, direct measurement of health outcomes by indicators has been explored", but adds that "where necessary", proxy outcomes based on processes linked to health outcomes that can be "substantially influenced" by CCGs have been employed.

Deputy Chief Executive and Director of Health and Social Care at NICE said: "We're delighted to be publishing the first menu of COF indicators recommended by the independent advisory committee. These potential indicators will support high quality commissioning of NHS services in England, to deliver the best health outcomes for patients."

She added that each indicator had been through public consultation and "feasibility testing" by the Health and Social Care Information Centre, "so commissioners can be reassured that they will work in practice".

Professor Danny Keenan, COF Advisory Committee Chair, said: "The broad range of clinical expertise within the independent committee, including GPs, hospital doctors, patients and commissioners, ensure that the menu of COF indicators recommended are workable, and can help improve the quality of commissioning to benefit patient care."

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels